Phosphodiesterase-5 inhibitors (PDE5-Is) promote smooth muscle relaxation through blocking the degradation of cGMP, and were proposed as a therapy for BPH in 2007 after men with erectile dysfunction reported relief of BPH symptoms while on PDE5-Is9, 10. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.